ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2024 · 112 positions · Total reported value $5.33B · Top-10 concentration 39.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2024 13F filing, ORBIMED ADVISORS LLC disclosed 112 equity positions with a combined reported value of $5.33B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 39.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were SVA ($340.00M), LLY ($280.69M), EWTX ($274.00M). By sector, the heaviest allocations are Health Care 77.0%, Consumer Discretionary 1.6%. Versus the prior quarter, allocation shifted toward Health Care (+8.7pp) and away from Other (-8.5pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q1 2024 were AVBP ($54.07M), CYTK ($47.86M), QTTB ($38.39M).

Of the 23 positions fully exited versus the prior quarter, the largest were RYZB ($147.05M), GRCL ($93.46M), UTHR ($84.90M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • AVBP ARRIVENT BIOPHARMA INC COM · $54.07M
  • CYTK CYTOKINETICS INC COM NEW · $47.86M
  • QTTB Q32 BIO INC · $38.39M
  • ESPR ESPERION THERAPEUTICS INC NE · $36.74M
  • PRAX PRAXIS PRECISION MEDICINES INC COM NEW · $28.10M
  • MLYS MINERALYS THERAPEUTICS INC COM · $26.10M
  • RNAM AVIDITY BIOSCIENCES INC · $25.37M
  • DYN DYNE THERAPEUTICS INC COM · $20.11M

Fully Exited (vs previous quarter)

  • RYZB RAYZEBIO INC · prev qtr: $147.05M
  • GRCL GRACELL BIOTECHNOLOGIES INC · prev qtr: $93.46M
  • UTHR UNITED THERAPEUTICS CORP DEL · prev qtr: $84.90M
  • THRX THERAVANCE INC · prev qtr: $71.74M
  • RCM R1 RCM INC · prev qtr: $50.77M
  • HUM HUMANA INC COM · prev qtr: $50.31M · history
  • IOVA Iovance Biotherapeutics Inc · prev qtr: $38.27M
  • FUSN FUSION PHARMACEUTICALS INC · prev qtr: $30.01M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 77.0%
Other 19.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.72M $340.00M 6.38%
6.38%
Hold
2 360.80K $280.69M 5.26%
5.26%
Reduce
3 15.02M $274.00M 5.14%
5.14%
Add
4 3.27M $224.17M 4.20%
4.20%
Reduce
5 493.10K $196.79M 3.69%
3.69%
Reduce
6 900.90K $194.26M 3.64%
3.64%
Add
7 1.32M $173.65M 3.26%
3.26%
Add
8 4.28M $160.97M 3.02%
3.02%
Add
9 9.00M $158.28M 2.97%
2.97%
Hold
10 1.17M $123.33M 2.31%
2.31%
Reduce
11 1.28M $111.66M 2.09%
2.09%
Reduce
12 2.68M $106.25M 1.99%
1.99%
Add
13 1.70M $105.98M 1.99%
1.99%
Hold
14 269.00K $96.27M 1.81%
1.81%
Hold
15 9.24M $94.44M 1.77%
1.77%
Hold
16 697.50K $90.30M 1.69%
1.69%
Hold
17 2.01M $87.26M 1.64%
1.64%
Reduce
18 168.10K $87.17M 1.64%
1.64%
Add
19 73.11M $85.54M 1.60%
1.60%
Hold
20 2.61M $85.44M 1.60%
1.60%
Reduce
21 1.71M $84.03M 1.58%
1.58%
Reduce
22 1.27M $83.99M 1.57%
1.57%
Hold
23 899.43K $82.26M 1.54%
1.54%
Reduce
24 132.00K $76.72M 1.44%
1.44%
Reduce
25 1.07M $72.83M 1.37%
1.37%
Reduce
26 1.39M $64.83M 1.22%
1.22%
Reduce
27 3.57M $63.49M 1.19%
1.19%
Reduce
28 151.60K $59.69M 1.12%
1.12%
Add
29 174.10K $58.49M 1.10%
1.10%
Add
30 423.10K $58.35M 1.09%
1.09%
Reduce
31 3.40M $54.67M 1.02%
1.02%
Reduce
32 5.78M $54.55M 1.02%
1.02%
Hold
33 3.03M $54.07M 1.01%
1.01%
New
34 4.00M $52.85M 0.99%
0.99%
Hold
35 10.91M $51.71M 0.97%
0.97%
Hold
36 122.70K $51.29M 0.96%
0.96%
Reduce
37 7.62M $49.98M 0.94%
0.94%
Hold
38 682.70K $47.86M 0.90%
0.90%
New
39 718.90K $47.77M 0.90%
0.90%
Reduce
40 22.36M $44.28M 0.83%
0.83%
Hold
41 12.89M $42.55M 0.80%
0.80%
Add
42 1.75M $41.63M 0.78%
0.78%
Hold
43 2.25M $38.39M 0.72%
0.72%
New
44 13.71M $36.74M 0.69%
0.69%
New
45 12.05M $35.97M 0.68%
0.68%
Hold
46 70.00K $34.63M 0.65%
0.65%
Hold
47 704.84K $30.54M 0.57%
0.57%
Add
48 2.72M $30.31M 0.57%
0.57%
Reduce
49 675.87K $29.14M 0.55%
0.55%
Reduce
50 460.51K $28.10M 0.53%
0.53%
New

FAQ

What did ORBIMED ADVISORS LLC buy in 2024-Q1?

In its 2024-Q1 13F filing, ORBIMED ADVISORS LLC reported 112 equity positions worth $5.33B in aggregate; its largest disclosed positions were SVA ($340.00M), LLY ($280.69M), EWTX ($274.00M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $5.33B of long equity holdings across 112 positions as of 2024-Q1. Top-10 holdings account for 39.9% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →